- Home
- IFRX vs SRTS Comparison
IFRX vs SRTS Comparison
Compare IFRX & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IFRX | SRTS |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 67.5M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IFRX | SRTS |
|---|---|---|
| Price | $1.14 | $3.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $8.50 | $8.00 |
| AVG Volume (30 Days) | ★ 765.5K | 60.6K |
| Earning Date | 11-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $73,729.00 | ★ $35,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,075.42 | $27.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $3.03 |
| 52 Week High | $2.77 | $9.08 |
Technical Indicators
Market Signals| Indicator | IFRX | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 48.03 |
| Support Level | $0.96 | $3.67 |
| Resistance Level | $1.16 | $3.90 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 88.08 | 45.54 |
Price Performance
Historical ComparisonAbout IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.